DE69404975D1 - (s)-alpha-phenyl-2-pyridinethanamin benzoat und seine verwendung als arzneimittel - Google Patents

(s)-alpha-phenyl-2-pyridinethanamin benzoat und seine verwendung als arzneimittel

Info

Publication number
DE69404975D1
DE69404975D1 DE69404975T DE69404975T DE69404975D1 DE 69404975 D1 DE69404975 D1 DE 69404975D1 DE 69404975 T DE69404975 T DE 69404975T DE 69404975 T DE69404975 T DE 69404975T DE 69404975 D1 DE69404975 D1 DE 69404975D1
Authority
DE
Germany
Prior art keywords
alpha
phenyl
benzoate
pyridinethanamine
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69404975T
Other languages
English (en)
Other versions
DE69404975T2 (de
Inventor
Robert Murray
Donald Mathisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Astra AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1993/000689 external-priority patent/WO1993020052A1/en
Application filed by Astra AB filed Critical Astra AB
Application granted granted Critical
Publication of DE69404975D1 publication Critical patent/DE69404975D1/de
Publication of DE69404975T2 publication Critical patent/DE69404975T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69404975T 1993-04-01 1994-04-05 (s)-alpha-phenyl-2-pyridinethanamin benzoat und seine verwendung als arzneimittel Expired - Lifetime DE69404975T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB1993/000689 WO1993020052A1 (en) 1992-04-03 1993-04-01 Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
PCT/GB1994/000716 WO1994022832A1 (en) 1993-04-01 1994-04-05 (s)-alpha-phenyl-2-pyridineethanamine benzoate and its use as a medicament

Publications (2)

Publication Number Publication Date
DE69404975D1 true DE69404975D1 (de) 1997-09-18
DE69404975T2 DE69404975T2 (de) 1997-12-18

Family

ID=10728731

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69404975T Expired - Lifetime DE69404975T2 (de) 1993-04-01 1994-04-05 (s)-alpha-phenyl-2-pyridinethanamin benzoat und seine verwendung als arzneimittel

Country Status (13)

Country Link
EP (1) EP0691958B1 (de)
JP (1) JP3023988B2 (de)
AT (1) ATE156814T1 (de)
AU (1) AU682350B2 (de)
CA (1) CA2159480C (de)
DE (1) DE69404975T2 (de)
DK (1) DK0691958T3 (de)
ES (1) ES2105679T3 (de)
FI (1) FI109019B (de)
GR (1) GR3025082T3 (de)
NO (1) NO304648B1 (de)
WO (1) WO1994022832A1 (de)
ZA (1) ZA942140B (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) * 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB9320273D0 (en) * 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
ATE135206T1 (de) * 1988-08-12 1996-03-15 Astra Ab Arylalkylamine und -amide mit krampflösender und nervenschützender wirkung
JP2514855B2 (ja) * 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
DK0633879T3 (da) * 1992-04-03 1998-09-28 Astra Ab Enantiomert 1-phenyl-2(2-pyridinyl) ethylamin til behandling af neurodegenerative sygdomme

Also Published As

Publication number Publication date
DE69404975T2 (de) 1997-12-18
NO953847L (no) 1995-11-22
FI954646A0 (fi) 1995-09-29
FI109019B (fi) 2002-05-15
NO304648B1 (no) 1999-01-25
NO953847D0 (no) 1995-09-28
EP0691958A1 (de) 1996-01-17
GR3025082T3 (en) 1998-01-30
AU6433794A (en) 1994-10-24
ZA942140B (en) 1994-10-03
DK0691958T3 (da) 1997-12-08
ATE156814T1 (de) 1997-08-15
JP3023988B2 (ja) 2000-03-21
CA2159480C (en) 2005-01-25
CA2159480A1 (en) 1994-10-13
EP0691958B1 (de) 1997-08-13
FI954646A (fi) 1995-11-29
ES2105679T3 (es) 1997-10-16
WO1994022832A1 (en) 1994-10-13
JPH08508475A (ja) 1996-09-10
AU682350B2 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
ZA941547B (en) Cosmetic applicator useful for cleansing moisturizing and protecting the skin from diaper rash
DE69128316D1 (de) Deodorant und dieses enthaltendes Produkt
DE69429821T2 (de) Farnesyl-derivate und diese enthaltende arzneimittel
DE69600048D1 (de) Kosmetisches Haarwaschmittel und dessen Verwendung
DE69333072D1 (de) Topisch anzuwendendes arzneimittel enthaltend hyaluronsäure und nsaids
ATE215373T1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE69420178T2 (de) Flüssigkeitsauftragegerät und Herstellung desselben
DE4494713T1 (de) Arylsulfonamidderivate und diese Derivate enthaltende Arzneimittel
DE69528165D1 (de) Transdermal verabreichbare grundlage und daraus hergestelltes transdermal verabreichbares arzneimittel
FI955786A0 (fi) Luonnontuotteiden ja vastaavien yhdisteiden käyttö sydän- ja verisuonisairauksien hoitoon
ATE156813T1 (de) (s)-alpha-phenyl-2-pyridinethanamin(s)-malat und seine verwendung als arzneimittel
ATE156814T1 (de) (s)-alpha-phenyl-2-pyridinethanamin benzoat und seine verwendung als arzneimittel
HUP9901165A3 (en) Thiamorphinans with neuroprotective activity, pharmaceutical compositions and use of the same
AU5627890A (en) Ozone decontamination of blood and blood products
GB9312780D0 (en) Therapeutic and cosmetic treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition